Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0894 • ACR Convergence 2022
DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
Anne Dupont¹, Arnaud Constantin², Martin Soubrier³ and Jérôme Avouac⁴, ¹Hôpital Cochin, AP-HP. Centre Université Paris-Cité, Paris, France, ²Toulouse University Hospital and University Toulouse III Paul Sabatier, Toulouse, France, ³Gabriel-Montpied Hospital, Clermont-Ferrand, France, ⁴University of Paris, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality that is largely due to cardiovascular disease (CVD). Ample evidence suggests that elevated γGT activity is…
Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Albert Pérez-Isidro¹, Raul Castellanos-Moreira¹, Juan Camilo Sarmiento-Monroy², Noemi de Moner¹, Maresa Grundhuber³, Odette Vinas¹, Raimon Sanmarti² and Estibaliz Ruiz-Ortiz¹, ¹Hospital Clinic of Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Thermo Fisher Scientific, Freiburg, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…
Abstract Number: 0926 • ACR Convergence 2022
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Renske Hebing¹, Imke Bartelink², Helen Gosselt³, Marry Lin³, Sandra Heil⁴, Robert De Jonge⁵ and Ron Mathot², ¹Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, ²Department of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁵Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Optimal dosing of low-dose methotrexate (MTX) is a challenge in rheumatoid arthritis (RA) because of substantial interpatient variation of response and because no stable…
Abstract Number: 1039 • ACR Convergence 2022
Differential Retention of Adalimumab and Etanercept Biosimilars Compared to Originator Treatments: Results of a Retrospective French Multicentre Study
Guillaume LARID¹, Guy Baudens², Alexis DANDURAND¹, Pascal COQUERELLE³, Vincent Goeb⁴, Marie-Hélène Guyot⁵, Laurent Marguerie⁶, Frédéric MAURY⁷, Viellard Eric⁸, Eric Houvenagel⁹, Jean Hugues SALMON¹⁰, René-Marc Flipo¹¹ and elisabeth gervais¹, ¹CHU Poitiers, Poitiers, France, ²Private practice, Valenciennes, France, ³CH Béthune, Béthune, France, ⁴CHU Amiens, Amiens, France, ⁵Private practice, Roubaix, France, ⁶Institut Calot, Berck-Sur-Mer, France, ⁷Private practice, Béthune, France, ⁸Private practice, St. Malo, France, ⁹Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ¹⁰Reims University Hospital, Reims, France, ¹¹CHU Lille, Boulogne-Billancourt, France
Background/Purpose: Studies have demonstrated equivalence in term of efficacy and safety of biosimilars (bsDMARDs) compared to the originals treatments (boDMARDs) and in switching situation. Less…
Abstract Number: 1207 • ACR Convergence 2022
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Huan Meng¹, Steven H Lam², Ho So¹ and Lai-shan Tam³, ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
Abstract Number: 1331 • ACR Convergence 2022
Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
Felipe Freire da Silva¹, Gisela Machado², ana Medeiros³, Karina Bonfiglioli⁴, Andrea Shimabuco², Liliam Takayama⁵, Rosa Pereira⁶ and Diogo Domiciano⁷, ¹FMUSP, Salvador, Brazil, ²FMUSP, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Jose Dos Campos, Brazil, ⁴Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵University of São Paulo, São Paulo, Brazil, ⁶Bone Metabolism Laboratory, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Hospital das Clinicas, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low bone mineral density (BMD) is a predictor of osteoporotic fracture. However, individuals with Rheumatoid Arthritis (RA) who sustain "osteoporosis-related" fractures frequently have normal…
Abstract Number: 1394 • ACR Convergence 2022
Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort
Laura Bricman¹, Emilie Sapart², Tatiana Sokolova³, Aleksandra avramovska² and Patrick Durez⁴, ¹Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁴Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Early RA patients (ERA pts) often present with different areas of joint involvement, but limited data exist to identify which specific joint locations may…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1429 • ACR Convergence 2022
Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Benjamin grenier³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
Abstract Number: 1604 • ACR Convergence 2022
Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial
Kevin D Deane¹, Christopher Striebich², Marie Feser³, Kristen Demoruelle³, LauraKay Moss⁴, Elizabeth Bemis³, Ashley Frazer-Abel⁴, Chelsie Fleischer⁴, Jeffrey Sparks⁵, Elizabeth Solow⁶, Judith James⁷, Joel Guthridge⁷, John Davis⁸, Jonathan Graf⁹, Jonathan Kay¹⁰, Maria Danila¹¹, S. Louis Bridges, Jr.¹², Lindsy Forbess¹³, James O'Dell¹⁴, Maureen McMahon¹⁵, Jennifer Grossman¹⁵, Diane Horowitz¹⁶, Athan Tiliakos¹⁷, Elena Schiopu¹⁸, David Fox¹⁹, Jeffrey Carlin²⁰, Cristina Arriens⁷, Vivian Bykerk¹², Reem Jan²¹, Mathilde Pioro²², M. Elaine Husni²³, Ana Fernandez-Pokorny²⁴, Sarah Walker²⁵, Susan Booher²⁶, Melissa Greenleaf²⁷, Margie Byron²⁵, Lynette Keyes-Elstein²⁵, Ellen Goldmuntz²⁸ and V. Michael Holers²⁹, ¹University of Colorado Denver Anschutz Medical Campus, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Denver, Denver, CO, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶UT Southwestern Medical Center, Dallas, TX, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Mayo Clinic, Rochester, MN, ⁹Ucsf, San Francisco, CA, ¹⁰Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ¹¹University of Alabama at Birmingham, Birmingham, AL, ¹²Hospital for Special Surgery, New York, NY, ¹³Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴University of Nebraska Medical Center, Omaha, NE, ¹⁵University of California Los Angeles, Los Angeles, CA, ¹⁶Northwell Health, Jericho, NY, ¹⁷Emory University, Roswell, GA, ¹⁸Michigan Medicine, Ann Arbor, MI, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰Virginia Mason Medical Center, Seattle, WA, ²¹University of Chicago, Chicago, IL, ²²University of Washington, Seattle, WA, ²³Cleveland Clinic, Cleveland, OH, ²⁴Essentia Health, Duluth, MN, ²⁵Rho, Chapel Hill, NC, ²⁶NIH NIAID, Bethesda, MD, ²⁷NIH, Rock Hill, SC, ²⁸NIAID/ NIH, Washington, DC, ²⁹University of Colorado, Denver, CO
Background/Purpose: The Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ClinicalTrials.gov NCT02603146) is a randomized, double-masked, placebo-controlled, multi-center (20 sites) clinical trial evaluating…
Abstract Number: 1684 • ACR Convergence 2022
A Potent Inhibitor of PAD4 Suppresses Histone Citrullination in Vitro and in Vivo
Gundula Min-Oo, Victor Lira, Debbie Ruelas, Upasana Mehra, Graham Pimm, Taylor Won, Jean-Philippe Belzile, Kelly Wang, Claire Ellis, Blake Bleier, Paqui Gonzalez Traves, Nikolai Novikov, Adam Schrier and Anita Niedziela-Majka, Gilead Sciences, Foster City, CA
Background/Purpose: Peptidyl arginine deaminase 4 (PAD4) catalyzes the conversion of arginine residues to citrulline, a post-translational modification that has been implicated in the auto-immune response…
Abstract Number: 1758 • ACR Convergence 2022
Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study
Camilla LIndegren¹, Emily Sonestedt¹, Emil Rydell¹, Linnea Arvidsson¹, Ulf Bergström¹ and Carl Turesson², ¹Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: There has been increasing interest in diet as a factor that may contribute to the development of rheumatoid arthritis (RA). There is limited and…
Abstract Number: 1953 • ACR Convergence 2022
Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively
Cristina Corrales¹, Fabricio Benavides Villanueva¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Virgi Portilla⁴, Ricardo Blanco⁵, Miguel Ángel González-Gay⁶ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but cardiovascular (CV) events…
Abstract Number: 1970 • ACR Convergence 2022
Detecting Inflammatory Changes in Seronegative Inflammatory Arthritis with Use of Musculoskeletal Ultrasound Studies
Clarice P. Lin¹ and Richard C. Chou², ¹University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Medicine, Buffalo, NY, ²University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, NY
Background/Purpose: Recent clinical practice has increasingly utilized musculoskeletal (MS) ultrasound studies to assess inflammation and soft-tissue abnormalities of the joints, such as synovitis and bone…
Abstract Number: 1987 • ACR Convergence 2022
Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study
CF Allaart¹, Sytske Anne Bergstra², Tom Huizinga¹ and Joy van der Pol³, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Netherlands, ³Leiden University Medical Center, Utrecht, Netherlands
Background/Purpose: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes. However, disease activity (DAS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].